Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:42:20.647Z.
Calculation as of: 2026-10-06T13:42:20.647Z.
Quote observation: 2026-10-06T13:32:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 787788ea5c712995087b0511470a3bc1500b131fb4a88c1f5ff44ca2612ce4c8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.23M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.71M | N/A | 3.11% | 2.71% | 2.71% |
| Envoy Medical, Inc. (COCH)vs › | $51.78M | N/A | 0.59% | 0.59% | 0.59% |
| biote Corp. (BTMD)vs › | $50.67M | 11.06% | 20.03% | 16.76% | 21.84% |
| Apollomics, Inc. (APLM)vs › | $50.51M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $50.37M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $49.84M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $53.99M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute